[1] Sanuki, N., Ono, A., Komatsu, E., Kamei, N., Akamine, S., Yamazaki, T., Mizunoe, S. and Maeda, T. (2012) Association of Computed Tomography-Detected Pulmonary Interstitial Changes with Severe Radiation Pneumonitis for Patients Treated with Thoracic Radiotherapy. Journal of Radiation Research, 53, 110-116.
https://doi.org/10.1269/jrr.110142
[2] Nieder, C., Grosu, A.L., Andratschke, N.H. and Molls, N. (2005) Proposal of Human Spinal Cord Reirradiation Dose Based on Collection of Data from 40 Patients. International Journal of Radiation Oncology*Biology*Physics, 61, 851-855.
https://doi.org/10.1016/j.ijrobp.2004.06.016
[3] Baziotis, N., Yakoumakis, E., Zissimopoulos, A., Geronicola-Trapali, X., Malamitsi, J. and Proukakis, C.H. (1998) Strontium-89 Chloride in the Treatment of Bone Metastases from Breast Cancer. Oncology, 55, 377-381.
https://doi.org/10.1159/000011881
[4] Fuster, D., Herranz, D., Vidal-Sicart, S., Munoz, M., Conill, C., Mateos, J.J., Martin, F. and Pons, F. (2000) Usefulness of Strontium-89 for Bone Pain Palliation in Metastatic Breast Cancer Patients. Nuclear Medicine Communications, 21, 623-626.
https://doi.org/10.1097/00006231-200007000-00004
[5] Dafermou, A., Colamussi, P., Giganti, M., Cittanti, C., Bestagno, M. and Piffanelli, A. (2001) A Multicentre Observational Study of Radionuclide Therapy in Patients with Painful Bone Metastases of Prostate Cancer. European Journal of Nuclear Medicine, 28, 788-798.
https://doi.org/10.1007/s002590100533
[6] Kraeber-Bodéré, F., Campion, L., Rousseau, C., Bourdin, S., Chatal, J.F. and Resche, I. (2000) Treatment of Bone Metastases of Prostate Cancer with Strontium-89 Chloride: Efficacy in Relation to the Degree of Bone Involvement. European Journal of Nuclear Medicine, 27, 1487-1493.
https://doi.org/10.1007/s002590000315
[7] Windsor, P.M. (2001) Predictors of Response to Strontium-89 (Metastron) in Skeletal Metastases from Prostate Cancer: Report of a Single Centre 10-Year Experience. Clinical Oncology, 13, 219-227.
https://doi.org/10.1053/clon.2001.9257
[8] Guidelines for the Therapeutic Administration of Strontium 89. Radiaton Safety Program Department of Human Service. Publication No. 95/0386.6.
[9] Blake, G.M. and Fogelman, I. (2013) Bone: Strontium Ranelate Does Not Have an Anabolic Effect on Bone. Nature Reviews Endocrinology, 9, 696-697.
https://doi.org/10.1038/nrendo.2013.210
[10] Ackery, D. and Yardley, J. (1993) Radionuclide-Targeted Therapy for the Management of Metastatic Bone Pain. Seminars in Oncology, 20, 27-31.
[11] McEwan, A.J. (2000) Use of Radionuclides for the Palliation of Bone Metastases. Seminars in Radiation Oncology, 10, 103-114.
https://doi.org/10.1016/S1053-4296(00)80047-8
[12] Yamada, K., Yoshimura, M. and Kaise, H. (2012) Current Use of Sr 89 Chloride with Zoledronic Acid Is Safe and Effective for Breast Cancer Patients with Painful Bone Metastases. Experimental and Therapeutic Medicine, 3, 226-230.
https://doi.org/10.3892/etm.2011.405